Press releases
- UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
- UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- UroGen Pharma Appoints David Lin as New Chief Commercial Officer
- UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
- UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
- UroGen Pharma to Participate at Upcoming Investor Conferences
- New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
More ▼
Key statistics
As of last trade, Urogen Pharma Ltd (0XOD:LSE) traded at 15.13, 72.45% above the 52 week low of 8.77 set on Jul 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 15.13 |
Average volume | 1.22k |
---|---|
Shares outstanding | 41.13m |
Free float | 37.25m |
P/E (TTM) | -- |
Market cap | 617.33m USD |
EPS (TTM) | -3.39 USD |
Data delayed at least 20 minutes, as of Jul 03 2024 14:32 BST.
More ▼